- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06963827
- Juicio original
Un estudio de mezagitamab en adultos con condición renal de nefropatía por IgA primaria
Un ensayo de fase 3 multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de mezagitamab (TAK-079) en los participantes del estudio con nefropatía IgA primaria en combinación con terapia de fondo estable
Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that build-up in the kidneys causing swelling (inflammation). Over time, this inflammation may lead to kidney damage and cause the kidneys to no longer work properly. The main aim of this study is to check how well mezagitamab changes protein levels in the urine (proteinuria) compared to placebo in adults with primary IgAN. A placebo looks like medicine but doesn't have any active ingredients in it. Other aims are to check how safe mezagitamab is and how well participants with primary IgAN can tolerate it compared to placebo, and to find out if and how well mezagitamab continues to maintain kidney function over the long term compared to placebo.
Participants will be placed in 1 of the 2 treatment groups; the main group and the open-label group. In the main group, participants will be placed by chance in either the mezagitamab or placebo treatment group at a 2:1 ratio. This means that out of 3 participants, 2 will receive mezagitamab and 1 will receive placebo. Participants can be in the study for 2 years (104 weeks). Participants will receive study treatment for about half a year (22 weeks) and then be observed for the remainder of the study (about 1.5 years). During observation, participants will continue to have check-ups about every month.
In the open-label group, a small number of participants who either have lower levels of protein in their urine or have kidneys that do not filter the blood well, will receive mezagitamab treatment. This will include participants who have previously received mezagitamab in another study, TAK-079-1006. Every participant will receive mezagitamab in the same way as those in the main group receiving mezagitamab.
During the study, participants will visit their study clinic several times.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Takeda Contact
- Número de teléfono: +1-877-825-3327
- Correo electrónico: medinfoUS@takeda.com
Ubicaciones de estudio
-
-
-
Mainz, Alemania, 55131
- Reclutamiento
- Universitaetsmedizin der Johannes - Gutenberg Universitaet Mainz
-
Contacto:
- Site Contact
-
Investigador principal:
- Julia Weinmann-Manke
-
-
North Rhine-Westphalia
-
Aachen, North Rhine-Westphalia, Alemania, 52074
- Reclutamiento
- Uniklinik RWTH Aachen
-
Contacto:
- Site Contact
-
Investigador principal:
- Claudia Seikrit
-
-
Thuringia
-
Jena, Thuringia, Alemania, 7747
- Reclutamiento
- Universitaetsklinikum Jena
-
Contacto:
- Site Contact
-
Investigador principal:
- Martin Busch
-
-
-
-
-
Ciudad Autonoma Buenos Aires, Argentina, 1280
- Reclutamiento
- Hospital Britanico de Buenos Aires
-
Contacto:
- Site Contact
-
Investigador principal:
- Hernan Trimarchi Jurado
-
Córdoba, Argentina, X5016
- Reclutamiento
- Clinica Privada Velez Sarsfield
-
Contacto:
- Site Contact
-
Investigador principal:
- Rafael Alberto Maldonado
-
-
Buenos Aires
-
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1425AGC
- Reclutamiento
- Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
-
Contacto:
- Site Contact
-
Investigador principal:
- Alejandra Smuclir Quevedo
-
-
La Plata
-
Buenos Aires, La Plata, Argentina, 1902
- Reclutamiento
- Framingham Centro Medico
-
Contacto:
- Site Contact
-
Investigador principal:
- Martin Mamberti
-
-
-
-
New South Wales
-
Liverpool, New South Wales, Australia
- Reclutamiento
- South Western Sydney Local Health District - University of New South Wales - Liverpool Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Beata Zahorowska
-
-
Queensland
-
Milton, Queensland, Australia
- Reclutamiento
- Core Research Group
-
Contacto:
- Site Contact
-
Investigador principal:
- David Colquhoun
-
-
Victoria
-
Box Hill, Victoria, Australia, 3128
- Reclutamiento
- Eastern Health
-
Investigador principal:
- Darren Lee
-
Contacto:
- Site Contact
-
Clayton, Victoria, Australia
- Reclutamiento
- Monash Heath - Monash University - Monash Medical Centre
-
Contacto:
- Site Contact
-
Investigador principal:
- Jessica Ryan
-
St Albans, Victoria, Australia, 3021
- Reclutamiento
- Western Health Sunshine Hospital
-
Investigador principal:
- Eugenia Pedagogos
-
Contacto:
- Site Contact
-
-
-
-
-
Linz, Austria, 4040
- Reclutamiento
- Johannes Kepler Universitat Linz, Universitatsklinik fur Innere 2
-
Contacto:
- Site Contact
-
Investigador principal:
- Alexander Moschen
-
Vienna, Austria, 1090
- Reclutamiento
- Medizinische Universitat Wien (Medical University of Vienna - Austria)
-
Investigador principal:
- Rainer Oberbauer
-
Contacto:
- Site Contact
-
-
-
-
Alberta
-
Calgary, Alberta, Canadá, T2R 0X7
- Reclutamiento
- Sheldon M. Chumir Health Centre
-
Contacto:
- Site Contact
-
Investigador principal:
- Louis Girard
-
-
Ontario
-
London, Ontario, Canadá, N6A5A5
- Reclutamiento
- London Health Sciences Centre
-
Contacto:
- Site Contact
-
Investigador principal:
- Matthew Weir
-
Toronto, Ontario, Canadá, M4G 3E8
- Reclutamiento
- Sunnybrook Health Sciences Centre
-
Contacto:
- Site Contact
-
Investigador principal:
- Michelle Hladunewich
-
-
-
-
-
Olomouc, Chequia, 779 00
- Reclutamiento
- Fakultni nemocnice Olomouc
-
Contacto:
- Site Contact
-
Investigador principal:
- Karel Krejci
-
Prague, Chequia
- Reclutamiento
- First Faculty of Medicine Charles University
-
Contacto:
- Site Contact
-
Investigador principal:
- Vladimir Tesar
-
-
Moravskoslezsk Kraj
-
Nový Jičín, Moravskoslezsk Kraj, Chequia, 741 01
- Reclutamiento
- Nemocnice AGEL Novy Jicin a.s
-
Contacto:
- Site Contact
-
Investigador principal:
- Vaclava Honova
-
-
-
-
-
Seoul, Corea del Sur, 3722
- Reclutamiento
- Severance Hospital, Yonsei University Health System
-
Investigador principal:
- Seung Hyeok Han
-
Contacto:
- Site Contact
-
Seoul, Corea del Sur, 3080
- Reclutamiento
- Seoul National University Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Dong Ki Kim
-
Seoul, Corea del Sur, 7061
- Reclutamiento
- Seoul National University Boramae Medical Center
-
Contacto:
- Site Contact
-
Investigador principal:
- Jung Pyo Lee
-
-
Gyeonggi-do
-
Yongin-si, Gyeonggi-do, Corea del Sur, 16995
- Reclutamiento
- Yongin Severance Hospital, Yonsei University Health System
-
Contacto:
- Site Contact
-
Investigador principal:
- Young Su Joo
-
-
Gyeonggido
-
Suwon, Gyeonggido, Corea del Sur, 16499
- Reclutamiento
- Ajou University Hospital-Primary Research Location
-
Contacto:
- Site Contact
-
Investigador principal:
- Inwhee Park
-
-
Seongnam
-
Seongnam-si, Seongnam, Corea del Sur, 13620
- Reclutamiento
- Seoul National University Bundang Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Ho-Jun Chin
-
-
-
-
-
Ljubljana, Eslovenia, 1000
- Reclutamiento
- University Medical Centre Ljubljana
-
Contacto:
- Site Contact
-
Investigador principal:
- Andreja Ales Rigler
-
Maribor, Eslovenia
- Reclutamiento
- University Clinical Centre Maribor
-
Contacto:
- Site Contact
-
Investigador principal:
- Sebastjan Bevc
-
-
-
-
-
Barcelona, España, 8035
- Reclutamiento
- Hospital Universitari Vall d'Hebron
-
Contacto:
- Site Contact
-
Investigador principal:
- Irene Agraz Pamplona
-
Barcelona, España, 8003
- Reclutamiento
- Hospital del Mar
-
Contacto:
- Site Contact
-
Investigador principal:
- Eva Rodriguez Garcia
-
Madrid, España, 28027
- Reclutamiento
- Universidad de Navarra - Clinica Universidad de Navarra
-
Contacto:
- Site Contact
-
Investigador principal:
- Jose Maria Mora Gutierrez
-
Madrid, España, 28040
- Reclutamiento
- Fundacion Jimenez Diaz
-
Contacto:
- Site Contact
-
Investigador principal:
- Roberto Scarpioni
-
Seville, España, 41013
- Reclutamiento
- Hospital Universitario Virgen del Rocio - PPDS
-
Contacto:
- Site Contact
-
Investigador principal:
- Manuel Lopez Mendoza
-
-
Barcelona
-
Badalona, Barcelona, España, 8915
- Reclutamiento
- Hospital Universitari Germans Trias i Pujol
-
Contacto:
- Site Contact
-
Investigador principal:
- Iara Karlla Da Silva Santos
-
-
Bizkaia
-
Barakaldo, Bizkaia, España, 48903
- Reclutamiento
- Hospital Universitario de Cruces
-
Contacto:
- Site Contact
-
Investigador principal:
- Laura Bueno Lopez
-
-
Navarre
-
Pamplona, Navarre, España, 31008
- Reclutamiento
- Universidad de Navarra - Clinica Universidad de Navarra
-
Contacto:
- Site Contact
-
Investigador principal:
- Jose Maria Mora Gutierrez
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233-2110
- Reclutamiento
- UAB Nephrology Research Clinic at Paula Building
-
Investigador principal:
- Dana Rizk
-
Contacto:
- Site Contact
-
Montgomery, Alabama, Estados Unidos, 36117
- Reclutamiento
- DCR Montgomery
-
Investigador principal:
- Vinayak Ramanath
-
Contacto:
- Site Contact
-
-
Arizona
-
Surprise, Arizona, Estados Unidos, 85374
- Reclutamiento
- Panoramic Health - Southwest Kidney Institute, PLC
-
Contacto:
- Site Contact
-
Investigador principal:
- Minesh Rajpal
-
-
California
-
Fremont, California, Estados Unidos, 94538
- Reclutamiento
- Panoramic Health - West Coast Kidney Institute (Fremont)
-
Contacto:
- Site Contact
-
Investigador principal:
- Varun Chawla
-
Los Angeles, California, Estados Unidos, 90022
- Reclutamiento
- Academic Medical Research Institute
-
Contacto:
- Site Contact
-
Investigador principal:
- Mohammed El-Shahwy
-
Los Angeles, California, Estados Unidos, 90095
- Reclutamiento
- UCLA University of California Los Angeles
-
Contacto:
- Site Contact
-
Investigador principal:
- Anjay Rastogi
-
Orange, California, Estados Unidos, 92868-3201
- Reclutamiento
- University of California Irvine
-
Contacto:
- Site Contact
-
Investigador principal:
- Ramy Hanna
-
San Francisco, California, Estados Unidos, 94118
- Reclutamiento
- Kaiser Permanente San Francisco Medical Center
-
Contacto:
- Site Contact
-
Investigador principal:
- Ali Poyan-Mehr
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32250
- Reclutamiento
- Panoramic Health - Florida Kidney Physicians, LLC (Jacksonville)
-
Contacto:
- Site Contact
-
Investigador principal:
- Prasanth Krish
-
Lauderdale Lakes, Florida, Estados Unidos, 33313-1607
- Reclutamiento
- South Florida Research Institute
-
Contacto:
- Site Contact
-
Investigador principal:
- Edouard Martin
-
Melbourne, Florida, Estados Unidos, 32901
- Reclutamiento
- Panoramic Health - Florida Kidney Physicians, LLC (Melbourne)
-
Contacto:
- Site Contact
-
Investigador principal:
- Claus Peter Spies
-
Miami, Florida, Estados Unidos, 33127
- Reclutamiento
- Bioresearch Partners
-
Contacto:
- Site Contact
-
Investigador principal:
- Jose Miguel Cardona-Guzman
-
Miami, Florida, Estados Unidos, 33176
- Reclutamiento
- Total Health and Research Center (THRC)
-
Contacto:
- Site Contact
-
Investigador principal:
- Jeffrey Maldonado
-
Orlando, Florida, Estados Unidos, 32806
- Reclutamiento
- CTR Oakwater, LLC
-
Contacto:
- Site Contact
-
Investigador principal:
- Arvind Madan
-
Pembroke Pines, Florida, Estados Unidos, 33029
- Reclutamiento
- Bioresearch Partners
-
Contacto:
- Site Contact
-
Investigador principal:
- Max Benjamin
-
Riverview, Florida, Estados Unidos, 33578
- Reclutamiento
- Panoramic Health - Florida Kidney Physicians, LLC (Tampa)
-
Contacto:
- Site Contact
-
Investigador principal:
- Amit Augustine Johnsingh
-
Sanford, Florida, Estados Unidos, 32771
- Reclutamiento
- Infigo Clinical Research LLC
-
Contacto:
- Site Contact
-
Investigador principal:
- Sayed Husain
-
-
Georgia
-
Columbus, Georgia, Estados Unidos, 31904
- Reclutamiento
- DCR Columbus
-
Contacto:
- Site Contact
-
Investigador principal:
- Tamorie Smith
-
East Point, Georgia, Estados Unidos, 30344
- Reclutamiento
- Panoramic Health - Southeast Kidney Associates
-
Contacto:
- Site Contact
-
Investigador principal:
- Charmaine Ifeoma Emelife
-
-
Idaho
-
Boise, Idaho, Estados Unidos, 83706
- Reclutamiento
- CARE Institute - Boise Kidney
-
Contacto:
- Site Contact
-
Investigador principal:
- Arnold Silva
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Reclutamiento
- Northwestern University
-
Contacto:
- Site Contact
-
Investigador principal:
- Yonatan Peleg
-
Rockford, Illinois, Estados Unidos, 61107
- Reclutamiento
- Panoramic Health - RNA of Rockford, LLC dba Rockford Nephrology Associates
-
Contacto:
- Site Contact
-
Investigador principal:
- Syed Mustafa Ahmed
-
-
Louisiana
-
Shreveport, Louisiana, Estados Unidos, 71101
- Reclutamiento
- Northwest Louisiana Nephrology
-
Contacto:
- Site Contact
-
Investigador principal:
- Marwan Kaskas
-
-
Michigan
-
Lansing, Michigan, Estados Unidos, 48911
- Reclutamiento
- Ingham Nephrology & Hypertension, P.C.
-
Contacto:
- Site Contact
-
Investigador principal:
- Brian Cousino
-
Pontiac, Michigan, Estados Unidos, 48341
- Reclutamiento
- Elixia MKC
-
Contacto:
- Site Contact
-
Investigador principal:
- Fahd Al-Saghir
-
Saint Joseph, Michigan, Estados Unidos, 49085
- Reclutamiento
- Panoramic Health - Lake Michigan Nephrology, PLC
-
Contacto:
- Site Contact
-
Investigador principal:
- Oliver Chambers Songlingco
-
-
Minnesota
-
Edina, Minnesota, Estados Unidos, 55435
- Reclutamiento
- DCR Edina
-
Contacto:
- Site Contact
-
Investigador principal:
- Shannon Doyle
-
-
Missouri
-
City of Saint Peters, Missouri, Estados Unidos, 63376
- Reclutamiento
- Elixia MNA
-
Contacto:
- Site Contact
-
Investigador principal:
- Gary Singer
-
Kansas City, Missouri, Estados Unidos, 64111
- Reclutamiento
- Clinical Research Consultants a JCCT Company
-
Contacto:
- Site Contact
-
Investigador principal:
- Ahmed Awad
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87109
- Reclutamiento
- Renal Medicine Associates - Frenova F1
-
Contacto:
- Site Contact
-
Investigador principal:
- Jayant Kumar
-
-
North Carolina
-
Winston-Salem, North Carolina, Estados Unidos, 27103
- Reclutamiento
- Brookview Hills Research Associates, LLC
-
Investigador principal:
- Nicholas McLean
-
Contacto:
- Site Contact
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45212
- Reclutamiento
- Panoramic Health - Kidney and Hypertension Center
-
Contacto:
- Site Contact
-
Investigador principal:
- James Davis
-
-
Pennsylvania
-
Media, Pennsylvania, Estados Unidos, 19063
- Reclutamiento
- Panoramic Health - Clinical Renal Associates, Ltd.
-
Contacto:
- Site Contact
-
Investigador principal:
- Nathan Okechukwu
-
Philadelphia, Pennsylvania, Estados Unidos, 19107
- Reclutamiento
- Thomas Jefferson University
-
Contacto:
- Site Contact
-
Investigador principal:
- Charlene Deng
-
-
Rhode Island
-
East Providence, Rhode Island, Estados Unidos, 02914
- Reclutamiento
- Panoramic Health - Nephrology Associates, Inc.
-
Contacto:
- Site Contact
-
Investigador principal:
- Larissa Kruger Gomes
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75230
- Reclutamiento
- Dallas Renal Group
-
Investigador principal:
- Irfan Agha
-
Contacto:
- Site Contact
-
El Paso, Texas, Estados Unidos, 79902
- Reclutamiento
- DCR - El Paso
-
Contacto:
- Site Contact
-
Investigador principal:
- Simon Rodriguez
-
Houston, Texas, Estados Unidos, 77054
- Reclutamiento
- Provecta Research Network
-
Contacto:
- Site Contact
-
Investigador principal:
- Sreedhar Mandayam
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- Houston Methodist Research Institute - Department of Medicine
-
Contacto:
- Site Contact
-
Investigador principal:
- Peter Nguyen
-
Katy, Texas, Estados Unidos, 77450
- Reclutamiento
- Nephrology Associates of Houston PLLC
-
Contacto:
- Site Contact
-
Investigador principal:
- Syed Hussain
-
San Antonio, Texas, Estados Unidos, 78215
- Reclutamiento
- Sun Research Institute
-
Contacto:
- Site Contact
-
Investigador principal:
- Reyes Leonel
-
San Antonio, Texas, Estados Unidos, 78251
- Reclutamiento
- DCR San Antonio
-
Contacto:
- Site Contact
-
Investigador principal:
- Tahira Alves
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84115
- Reclutamiento
- Utah Kidney Research Institute
-
Contacto:
- Site Contact
-
Investigador principal:
- Sanjiv Anand
-
-
Virginia
-
Arlington, Virginia, Estados Unidos, 22205
- Reclutamiento
- Panoramic Health - Virginia Nephrology Group
-
Contacto:
- Site Contact
-
Investigador principal:
- Renuka Sothinathan
-
-
West Virginia
-
Morgantown, West Virginia, Estados Unidos, 26506
- Reclutamiento
- West Virginia University
-
Contacto:
- Site Contact
-
Investigador principal:
- Bethany Pellegrino
-
-
-
-
-
Bordeaux, Francia, 33076
- Reclutamiento
- CHU Bordeaux, CHU Pellegrin
-
Contacto:
- Site Contact
-
Investigador principal:
- Claire Rigothier
-
Limoges, Francia, 87042
- Reclutamiento
- CHU Limoges Service de Nephrology
-
Contacto:
- Site Contact
-
Investigador principal:
- Fatouma Toure
-
Montpellier, Francia, 34090
- Reclutamiento
- Centre Hospitalier Universitaire de Montpellier (CHU Montpellier) - Hopital Lapeyronie
-
Contacto:
- Site Contact
-
Investigador principal:
- Moglie Le Quintrec
-
Nantes, Francia, 44093
- Reclutamiento
- CHU de Nantes
-
Contacto:
- Site Contact
-
Investigador principal:
- Simon Ville
-
Paris, Francia, 75020
- Reclutamiento
- Hospital Tenon
-
Contacto:
- Site Contact
-
Investigador principal:
- Khalil Karoui
-
-
Paris
-
Créteil, Paris, Francia, 94000
- Reclutamiento
- Hospital Henri Mondor
-
Contacto:
- Site Contact
-
Investigador principal:
- Vincent Audard
-
-
-
-
Hong Kong Island
-
Hong Kong, Hong Kong Island, Hong Kong
- Reclutamiento
- The University of Hong Kong - Department of Medicine
-
Investigador principal:
- Sydney Chi Wai Tang
-
Contacto:
- Site Contact
-
-
-
-
-
Budapest, Hungría, 1083
- Reclutamiento
- Semmelweis Egyetem - Belgyogyaszati es Onkologiai Klinika (I.sz. Belgyogyaszati Klinika)
-
Contacto:
- Site Contact
-
Investigador principal:
- Akos Petho
-
-
-
-
-
Bologna, Italia, 40138
- Reclutamiento
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
-
Contacto:
- Site Contact
-
Investigador principal:
- Gaetano La Manna
-
Brescia, Italia, 25124
- Reclutamiento
- ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia
-
Contacto:
- Site Contact
-
Investigador principal:
- Federica Mescia
-
Genoa, Italia, 16132
- Reclutamiento
- IRCCS Ospedale Policlinico San Martino
-
Contacto:
- Site Contact
-
Investigador principal:
- Francesca Viazzi
-
Messina, Italia, 98122
- Reclutamiento
- Az Ospedaliera Universitaria Policlinico G Martino
-
Contacto:
- Site Contact
-
Investigador principal:
- Domenico Santoro
-
Milan, Italia, 20100
- Reclutamiento
- Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
-
Contacto:
- Site Contact
-
Investigador principal:
- Giuseppe Castellano
-
Pavia, Italia, 27100
- Reclutamiento
- Istituto Maugeri IRCCS Pavia
-
Investigador principal:
- Ciro Esposito
-
Contacto:
- Site Contact
-
Piacenza, Italia, 29121
- Reclutamiento
- Azienda Unita Sanitaria Locale Piacenza (AUSL) Ospedale "Guglielmo da Saliceto
-
Contacto:
- Site Contact
-
Investigador principal:
- Roberto Scarpioni
-
Torino, Italia, 10126
- Reclutamiento
- AOU Citta della Salute e della Scienza di Torino
-
Contacto:
- Site Contact
-
Investigador principal:
- Luigi Biancone
-
-
-
-
Aichi-ken
-
Kasugai-Shi, Aichi-ken, Japón, 486-8510
- Reclutamiento
- Kasugai Municipal Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Yosuke Saka
-
Nagoya, Aichi-ken, Japón, 466-8650
- Reclutamiento
- Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Shoji Saito
-
Toyoake-shi, Aichi-ken, Japón, 470-1192
- Reclutamiento
- Fujita Health University Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Naotake Tsuboi
-
-
Chiba
-
Chiba, Chiba, Japón, 260-8712
- Reclutamiento
- National Hospital Organization Chiba Medical Center Chibahigashi National Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Takehiko Kawaguchi
-
-
Fukuoka
-
Fukuoka, Fukuoka, Japón, 812-8582
- Reclutamiento
- Kyushu University Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Toshiaki Nakano
-
-
Fukushima
-
Fukushima, Fukushima, Japón, 960-1295
- Reclutamiento
- Fukushima Medical University Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Kazama Junichiro
-
-
Hiroshima
-
Hiroshima, Hiroshima, Japón, 734-8551
- Reclutamiento
- Hiroshima University Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Takao Masaki
-
-
Hokkaido
-
Sapporo, Hokkaido, Japón, 060-8648
- Reclutamiento
- Hokkaido University Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Daigo Nakazawa
-
-
Kanagawa
-
Kamakura-shi, Kanagawa, Japón, 247-8533
- Reclutamiento
- Shonan Kamakura General Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Hidaka Sumi
-
Kawasaki-shi, Kanagawa, Japón, 213-8587
- Reclutamiento
- Toranomon Hospital Kajigaya
-
Contacto:
- Site Contact
-
Investigador principal:
- Naoki Sawa
-
Yokohama, Kanagawa, Japón, 236-0004
- Reclutamiento
- Yokohama City University Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Kouichi Tamura
-
-
Miyagi
-
Sendai, Miyagi, Japón, 981-3281
- Reclutamiento
- Japan Community Health care Organization Sendai Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Santoru Sanada
-
-
Nara
-
Kashihara-shi, Nara, Japón, 634-8522
- Reclutamiento
- Nara Medical University Hospital
-
Investigador principal:
- Kazuhiko Tsuruya
-
Contacto:
- Site Contact
-
Nara, Nara, Japón, 630-8581
- Reclutamiento
- Nara Prefecture General Medical Center
-
Contacto:
- Site Contact
-
Investigador principal:
- Hideo Tsushima
-
-
Oita Prefecture
-
Yufu-shi, Oita Prefecture, Japón, 879-5593
- Reclutamiento
- Oita University Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Fukuda Akihiro
-
-
Osaka
-
Osaka, Osaka, Japón, 530-8480
- Reclutamiento
- Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofuka
-
Contacto:
- Site Contact
-
Investigador principal:
- Takeshi Matsubara
-
-
Saitama
-
Koshigaya-shi, Saitama, Japón, 343-8555
- Reclutamiento
- Dokkyo Medical University Saitama Medical Center
-
Investigador principal:
- Tetsuro Takeda
-
Contacto:
- Site Contact
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japón, 113-8431
- Reclutamiento
- Juntendo University Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Yusuke Suzuki
-
Shinjuku-Ku, Tokyo, Japón, 160-0023
- Reclutamiento
- Tokyo Medical University Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Takahito Moriyama
-
-
Yamanashi
-
Chuo-shi, Yamanashi, Japón, 409-3898
- Reclutamiento
- University of Yamanashi Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Ayumu Nakashima
-
-
-
-
-
Kuala Lumpur, Malasia, 50603
- Reclutamiento
- Universiti Malaya Medical Centre (UMMC)
-
Contacto:
- Site Contact
-
Investigador principal:
- Soo Kun Lim
-
-
Kuala Lumpur
-
Kuala Lumpur, Kuala Lumpur, Malasia, 56000
- Reclutamiento
- Universiti Kebangsaan Malaysia (UKM) - Medical Centre (Pusat Perubatan) (Hospital Canselor Tuanku Muhriz (HCTM))
-
Contacto:
- Site Contact
-
Investigador principal:
- Lydia Kamaruzaman
-
-
Pahang
-
Kuantan, Pahang, Malasia, 25100
- Reclutamiento
- Hospital Tengku Ampuan Afzan
-
Contacto:
- Site Contact
-
Investigador principal:
- Fariz Safhan Mohamad Nor
-
-
Perak
-
Taiping, Perak, Malasia, 34000
- Reclutamiento
- Hospital Taiping
-
Contacto:
- Site Contact
-
Investigador principal:
- Kok Seng Teng
-
-
Selangor
-
Kajang, Selangor, Malasia, 43000
- Reclutamiento
- Hospital Sultan Idris Shah Serdang (Hospital Serdang)
-
Contacto:
- Site Contact
-
Investigador principal:
- Li Lian Tay
-
Subang Jaya, Selangor, Malasia, 47500
- Reclutamiento
- Sunway Medical Centre (SMC)
-
Contacto:
- Site Contact
-
Investigador principal:
- Rosnawati Yahya
-
-
-
-
-
Bergen, Noruega, 5021
- Reclutamiento
- Haukeland Universitetssjukehus
-
Contacto:
- Site Contact
-
Investigador principal:
- Thomas Knoop
-
Grålum, Noruega, 1714
- Reclutamiento
- Sykehuset Ostfold
-
Contacto:
- Site Contact
-
Investigador principal:
- Dumitrescu Ioana-Elena
-
Stavanger, Noruega
- Reclutamiento
- Stavanger Universitetssjukehus - Helse Stavanger HF
-
Contacto:
- Site Contact
-
Investigador principal:
- Goransson Lasse
-
Trondheim, Noruega, 7030
- Reclutamiento
- Universitetssykehuset I Trondheim - St. Olavs Hospital - Nevroklinikken
-
Contacto:
- Site Contact
-
Investigador principal:
- Yngvar Haaskjold
-
-
Akershus
-
Lorenskog, Akershus, Noruega, 1478
- Reclutamiento
- Akershus University Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Bartlomiej Witczak
-
-
Vestfold
-
Tønsberg, Vestfold, Noruega
- Reclutamiento
- Sykehuset I Vestfold
-
Contacto:
- Site Contact
-
Investigador principal:
- Kjellevold Stig Arne
-
-
-
-
-
Leiden, Países Bajos, 2333 ZA
- Reclutamiento
- Leids Universitair Medisch Center
-
Contacto:
- Site Contact
-
Investigador principal:
- Joris Rotmans
-
Nieuwegein, Países Bajos, 3435CM
- Reclutamiento
- Sint Antonius ziekenhuis Utrecht/Nieuwegein
-
Contacto:
- Site Contact
-
Investigador principal:
- Gurbey Ocak
-
Nijmegen, Países Bajos, 6525 GA
- Reclutamiento
- Radboud Universitair Medisch Centrum
-
Contacto:
- Site Contact
-
Investigador principal:
- Raphael Duivenvoorden
-
Utrecht, Países Bajos, 3584 CX
- Reclutamiento
- UMC Utrecht
-
Contacto:
- Site Contact
-
Investigador principal:
- Sabine Meijvis
-
-
North Holland
-
Amsterdam, North Holland, Países Bajos, 1105 AZ
- Reclutamiento
- Amsterdam UMC - Locatie AMC (Academisch Medisch Centrum)
-
Contacto:
- Site Contact
-
Investigador principal:
- Marc Hilhorst
-
-
-
-
-
Gmina Świecie, Polonia, 86-100
- Reclutamiento
- Nowy Szpital Sp Zo.o
-
Contacto:
- Site Contact
-
Investigador principal:
- Andrzej Brymora
-
Krakow, Polonia, 31-559
- Reclutamiento
- SCM Sp. z o.o.
-
Contacto:
- Site Contact
-
Investigador principal:
- Dariusz Aksamit
-
Lodz, Polonia
- Reclutamiento
- Indywidualna Specjalistyczna Praktyka Lekarska
-
Investigador principal:
- Michal Nowicki
-
Contacto:
- Site Contact
-
Wroclaw, Polonia, 50-981
- Reclutamiento
- 4th Military Clinical hospital /Polyclinic SP ZOZ
-
Contacto:
- Site Contact
-
Investigador principal:
- Magdalena Krajewska
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Porcelana, 100034
- Reclutamiento
- Peking University First Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Jicheng Lv
-
Changping, Beijing Municipality, Porcelana, 102218
- Reclutamiento
- Beijing Tsinghua Changgung Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Yuehong Li
-
-
Fujian
-
Xiamen, Fujian, Porcelana, 361004
- Reclutamiento
- Zhongshan Hospital Xiamen University
-
Contacto:
- Site Contact
-
Investigador principal:
- Bo Xu
-
-
Guangdong
-
Guangdong, Guangdong, Porcelana, Guangdong
- Reclutamiento
- The First Affiliated Hospital of Sun Yat-sen University
-
Contacto:
- Site Contact
-
Investigador principal:
- Wei Chen
-
Guangzhou, Guangdong, Porcelana, 510080
- Reclutamiento
- Guangdong General Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Zhiming Ye
-
Shenzhen, Guangdong, Porcelana, 518000
- Reclutamiento
- Peking University Shenzhen Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Zu-Ying Xiong
-
-
Hunan
-
Changsha, Hunan, Porcelana, 410013
- Reclutamiento
- The Third Xiangya Hospital of Central South University Yuelu District
-
Investigador principal:
- Hao Zhang
-
Contacto:
- Site Contact
-
-
Inner Mongolia
-
Baotou, Inner Mongolia, Porcelana, 14010
- Reclutamiento
- The First Affiliated Hospital of Baotou Medical College
-
Contacto:
- Site Contact
-
Investigador principal:
- Zengyan Li
-
-
Jiangsu
-
Nanjing, Jiangsu, Porcelana, 210009
- Reclutamiento
- Zhongda Hospital Southeast University
-
Contacto:
- Site Contact
-
Investigador principal:
- Liu Bicheng
-
Nantong, Jiangsu, Porcelana, 226001
- Reclutamiento
- Affiliated Hospital of Nantong University
-
Contacto:
- Site Contact
-
Investigador principal:
- Xinzhong Huang
-
Wuxi, Jiangsu, Porcelana, 214023
- Reclutamiento
- Wuxi People's Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Liang Wang
-
-
Jiangxi
-
Nanchang, Jiangxi, Porcelana, 330006
- Reclutamiento
- The First Affiliated Hospital of Nanchang University
-
Contacto:
- Site Contact
-
Investigador principal:
- Yan Yan
-
-
Shandong
-
Jinan, Shandong, Porcelana, 250012
- Reclutamiento
- Shandong University - Qilu Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Xiang-Dong Yang
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Porcelana, 200000
- Reclutamiento
- Shanghai Jiao Tong University School of Medicine (SJTUSM) - Renji Hospital - Eastern Branch
-
Contacto:
- Site Contact
-
Investigador principal:
- Leyi Gu
-
Shanghai, Shanghai Municipality, Porcelana, 200025
- Reclutamiento
- Ruijin Hospital of Shanghai Jiaotong University School of Medicine
-
Contacto:
- Site Contact
-
Investigador principal:
- Jingyuan Xie
-
-
Sichuan
-
Chengdu, Sichuan, Porcelana, 610000
- Reclutamiento
- West China Hospital Sichuan University
-
Investigador principal:
- Ping Fu
-
Contacto:
- Site Contact
-
Chengdu, Sichuan, Porcelana, 610072
- Reclutamiento
- Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Guisen Li
-
Yibin, Sichuan, Porcelana, 644099
- Reclutamiento
- The Second People's Hospital of Yibin
-
Contacto:
- Site Contact
-
Investigador principal:
- Deqiong Xie
-
-
Xiangzhou District, Guangdong Province
-
Zhuhai, Xiangzhou District, Guangdong Province, Porcelana, 519000
- Reclutamiento
- Fifth Affiliated Hospital Sun Yat-Sen University
-
Contacto:
- Site Contact
-
Investigador principal:
- Cheng Wang
-
-
Zhejiang
-
Hangzhou, Zhejiang, Porcelana
- Reclutamiento
- The Second Affiliated Hospital, Zhejiang University, School of Medicine
-
Contacto:
- Site Contact
-
Investigador principal:
- Kunling Ma
-
Ningbo, Zhejiang, Porcelana, 315010
- Reclutamiento
- The First Affiliated Hospital of Ningbo University
-
Contacto:
- Site Contact
-
Investigador principal:
- Xueyan Bian
-
-
-
-
-
Canterbury, Reino Unido, CT1 3PA
- Reclutamiento
- Kent & Canterbury Hospital, Canterbury
-
Contacto:
- Site Contact
-
Investigador principal:
- Tharindra Somasinghe
-
Hull, Reino Unido
- Reclutamiento
- Hull University Teaching Hospitals NHS Trust
-
Contacto:
- Site Contact
-
Investigador principal:
- Sunil Bhandari
-
Leicester, Reino Unido
- Reclutamiento
- Leicester General Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Chee Kay Cheung
-
London, Reino Unido, WC2R 2LS
- Reclutamiento
- King's College Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Sapna Shah
-
London, Reino Unido, SW17 0QT
- Reclutamiento
- St George's University Hospitals NHS Foundation Trust
-
Contacto:
- Site Contact
-
Investigador principal:
- Richard Hull
-
Nottingham, Reino Unido
- Reclutamiento
- Nottingham University Hospitals NHS Trust - City Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Matthew Hall
-
Preston, Reino Unido, PR29HT
- Reclutamiento
- Lancashire Teaching Hospital NHS Foundation Trust
-
Contacto:
- Site Contact
-
Investigador principal:
- Arvind Ponnusamy
-
Sheffield, Reino Unido
- Reclutamiento
- Northern General Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Arif Khwaja
-
-
Greater London
-
London, Greater London, Reino Unido, SE1 9RT
- Reclutamiento
- Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Dimitrios-Anestis Moutzouris
-
-
United Kingdom of Great Britain and Northern Ireland
-
Birmingham, United Kingdom of Great Britain and Northern Ireland, Reino Unido
- Reclutamiento
- Birmingham Heartlands Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Bamidele Tokunbo Ajayi
-
-
-
-
-
Singapore, Singapur
- Reclutamiento
- National University Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Boon Wee Teo
-
Singapore, Singapur, 169608
- Reclutamiento
- Singapore General Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Jason Choo
-
Singapore, Singapur, 308433
- Reclutamiento
- Tan Tock Seng Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- See Cheng Yeo
-
-
-
-
-
Linköping, Suecia
- Reclutamiento
- Renal Medicine Linkoping University/ Linkoping University Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Annette Bruchfeld
-
-
-
-
-
Zurich, Suiza, 8091
- Reclutamiento
- University Hospital Zurich
-
Contacto:
- Site Contact
-
Investigador principal:
- Britta George
-
-
-
-
-
Kaohsiung City, Taiwán, 807
- Reclutamiento
- Kaohsiung Medical University - Chung-Ho Memorial Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Yi Wen Chiu
-
New Taipei City, Taiwán
- Reclutamiento
- Taipei Medical University Shuang Ho Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Mai-Szu Wu
-
Taichung, Taiwán, 40705
- Reclutamiento
- Taichung Veterans General Hospital
-
Investigador principal:
- Ming-Ju Wu
-
Contacto:
- Site Contact
-
Taichung, Taiwán
- Reclutamiento
- China Medical University Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Ping-Chin Lai
-
Zhongzheng, Taiwán, 100
- Reclutamiento
- National Taiwan University Hospital
-
Contacto:
- Site Contact
-
Investigador principal:
- Jenq-Wen Huang
-
-
-
-
-
Kocaeli, Turquía (Türkiye)
- Reclutamiento
- Kocaeli Universitesi Tip Fakultesi Arastirma ve Uygulama Hastanesi
-
Contacto:
- Site Contact
-
Investigador principal:
- Necmi Eren
-
-
Battalgazi
-
Malatya, Battalgazi, Turquía (Türkiye), 44280
- Reclutamiento
- Turgut Ozal Medical Center
-
Contacto:
- Site Contact
-
Investigador principal:
- Ozkan Ulutas
-
-
Gaziantep
-
Şahinbey, Gaziantep, Turquía (Türkiye), 27310
- Reclutamiento
- Gaziantep Universitesi Sahinbey Arastirma ve Uygulama Hastanesi
-
Contacto:
- Site Contact
-
Investigador principal:
- Fatih Mehmet Erdur
-
-
Istanbul
-
Fatih, Istanbul, Turquía (Türkiye), 34098
- Reclutamiento
- Istanbul Universitesi Cerrahpasa Tip Fakultesi
-
Contacto:
- Site Contact
-
Investigador principal:
- Nurhan Seyahi
-
-
Melikgazi
-
Kayseri, Melikgazi, Turquía (Türkiye), 38039
- Reclutamiento
- Erciyes University
-
Contacto:
- Site Contact
-
Investigador principal:
- Bulent Tokgoz
-
-
Onikisubat
-
Kahramanmaraş, Onikisubat, Turquía (Türkiye), 46040
- Reclutamiento
- Kahramanmaras Sutcu Imam Universitesi Tip Fakultesi Avsar Mah
-
Contacto:
- Site Contact
-
Investigador principal:
- Orcum Altunoren
-
-
Selcuklu
-
Konya, Selcuklu, Turquía (Türkiye), 42280
- Reclutamiento
- Necmettin Erbakan University
-
Contacto:
- Site Contact
-
Investigador principal:
- Kultigin Turkmen
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
- Inclusion Criteria:
To be eligible to participate in this trial, participants must meet all the following criteria:
-
Either UPCR greater than or equal to (≥) 0.8 gram per gram (g/g) or urine protein excretion (UPE) ≥1 grams per day (g/day), calculated from at least one 24-hour urine collection during the screening period (or pre-screening, if applicable) (only applicable for the main trial).
-
eGFR greater than (>)30 milliliters per minute per 1.73 meter square (mL/min/1.73m^2) at screening based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (only applicable for the main trial).
-
No prior exposure to anti- cluster of differentiation 38 (CD38) therapy period (except for open-label cohort participants meeting Inclusion Criterion No. 10.a).
-
The participant is aged ≥ 18 years or the local legal age as applicable.
-
The participant (and the participant's legally acceptable representative, as applicable per local regulations or determination) has provided informed consent (that is, in writing, documented via a signed and dated informed consent form [ICF]) and any required privacy authorization before the initiation of any clinical trial procedures.
-
Diagnosis of primary immunoglobulin A nephropathy (IgAN) supported by a renal biopsy report that is dated more recently than 10 years before the signing of the informed consent for the clinical trial. The redacted report must be made available for review. A renal biopsy must be performed during screening for participants without a biopsy report within 10 years.
-
Participants must be on stable renin-angiotensin-aldosterone system (RAAS) inhibitor therapy with an angiotensin-converting enzyme inhibitor (ACE-I) and/or angiotensin receptor blocker (ARB) or endothelin receptor antagonist (ERA) or mineralocorticoid receptor antagonist (MRA) agent for at least 12 weeks before signing the ICF with dosing at the maximally tolerated or labeled dose as determined by the investigator, with the intent to continue stable dosing during the clinical trial. Those intolerant of RAAS inhibitor therapy are potentially eligible after consultation with the medical monitor. Intolerance is defined as a documented side effect causing discontinuation of the therapy.
-
Resting blood pressure less than or equal to (≤)150 millimeters of mercury (mmHg) systolic and ≤100 mmHg diastolic.
-
Female participants of childbearing potential who are not pregnant during screening (confirmed by negative serum human chorionic gonadotropin [hCG]) and on Visit 1 before first dose of trial intervention (confirmed by negative urine pregnancy test).
-
Any one of the following (only applicable for participants in the open-label cohort):
-
Participants in Trial TAK-079-1006 who completed the Week 96 visit or the retreatment period with either UPCR >0.5 g/g or UPE >0.5 g/d calculated from a 24-hour urine collection during the screening period (or pre-screening, if applicable) and eGFR >30 mL/min/1.73m^2 at screening based on the CKD-EPI formula.
-
UPCR <0.8 g/g and UPE ≥0.75 and <1.0 g/day, by 24-hour urine collection during the screening period (or pre-screening, if applicable) and eGFR > 30 mL/min/1.73m^2 at screening based on the CKD-EPI formula.
-
UPCR ≥ 0.8 g/g or UPE ≥ 1.0 g/d by 24-hour urine collection during the screening period (or pre-screening, if applicable) and eGFR ≥25 and ≤30 mL/min/1.73m^2 at screening based on the CKD-EPI formula.
- Exclusion Criteria:
-
A participant who meets any of the following criteria will be excluded from participation in this trial:
-
Kidney biopsy exhibiting significant concomitant renal disease other than IgAN (for example, diabetic nephropathy, lupus nephritis, minimal change disease).
-
Secondary IgAN (such as with significant liver disease, inflammatory bowel disease, and seronegative spondyloarthropathies), and immunoglobulin A (IgA) vasculitis.
-
Evidence of rapidly progressive glomerulonephritis (loss of ≥50% of eGFR within 3 months before the signing of the ICF).
-
Diagnosis of nephrotic syndrome defined as 24-hour proteinuria >3.5 g/day and hypoalbuminemia (<3.0 grams per deciliter [g/dL]) with or without peripheral edema.
-
Renal or other organ transplantation prior to or expected during the clinical trial.
-
Treatment with oral immunosuppressive agents (including cyclophosphamide, mycophenolate mofetil, cyclosporine, azathioprine, calcineurin inhibitors) or biologic therapy for immunomodulation (including immunomodulatory monoclonal or polyclonal antibodies) within 6 months (both B-cell and non-B-cell directed agents) before signing of the ICF.
-
If the participant has received anti-CD20 treatment, the participant is excluded if either of the following apply:
- The last dose was received within 6 months before the signing of the ICF.
- The last dose was received between 6 and 12 months before the signing of the ICF and the participant has a CD19+ count below the lower limit of normal.
Note: Participants who have received the last dose of anti-CD20 treatment >12 months before the signing of the ICF are not excluded from clinical trial participation based on this criterion and are not required to undergo CD19+ testing.
-
Within 4 months of the screening visit, use of either a) systemic corticosteroids at an average dose of 40 milligrams (mg) prednisone equivalent or higher for more than 14 days or b) oral budesonide delayed release capsules.
-
The participant has received a live or live-attenuated vaccine within 4 weeks before signing the ICF or has any live or live-attenuated vaccine planned during the clinical trial.
-
Participation in any other investigational drug trial (including vaccine trial) with receipt of at least 1 dose of investigational drug, or has been exposed to another investigational agent within 4 weeks or 5 half-lives, whichever is longer, before Visit 1.
-
The participant has active infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).
-
The participant has had any of the following types of infections within the specified timeframes where applicable:
- Active bacterial, viral, or fungal infection (except for the common cold and onychomycosis), or any other serious infection within 2 weeks of signing the ICF. Any anti-infective course for infection must be completed at least 2 weeks before Visit 1.
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) infection within 4 weeks of signing the ICF.
- Opportunistic infection or treatment for an opportunistic infection less than or equal to (≤)12 weeks before signing the ICF.
- Active tuberculosis (TB), any history of prior active TB, or any signs or symptoms of active TB infection (including but not limited to chronic fever, chronic productive cough, night sweats, weight loss, or malnutrition) as judged by the investigator.
- For participants in European Union (EU) member states, positive or 2 indeterminant QuantiFERON results, unless there is documentation of prior complete treatment for latent TB, or participant has initiated prophylaxis based on local guidelines and in consultation with a pulmonology or infectious disease specialist prior to the first administration of IMP.
-
In the opinion of the investigator, the participant is currently experiencing any medical condition that might interfere with participation in the trial (for example, significant ocular, cardiovascular, pulmonary, hematologic, gastrointestinal, endocrinologic, hepatic, renal, neurologic, malignancy, infectious disease, immunodeficiency, or alcohol and drug abuse), that poses an added risk for the participant or could confound the assessment of trial results.
-
In the opinion of the investigator, the participant has a serious medical or psychiatric illness that could potentially interfere with the completion of treatment.
-
The participant has a history of major surgery within 3 months before screening (or longer, at the discretion of the investigator); or, either has a planned tonsillectomy or underwent a tonsillectomy within 6 months before screening.
Note: Major surgery typically requires at least 1 night in the hospital.
-
History of malignancy (including myelodysplastic syndrome) within 5 years of signing the ICF, except for adequately treated non-melanoma skin cancer, superficial bladder cancer, and curatively treated cervical carcinoma-in-situ.
-
The participant has a history of a severe allergic or anaphylactic reaction to recombinant proteins or excipients used in the mezagitamab or placebo formulation.
-
The participant has (1) been diagnosed with or has suspected chronic obstructive pulmonary disease (COPD) or asthma and (2) has a prebronchodilatory forced expiratory volume in 1 second (FEV1) <50% of predicted normal at screening.
-
The participant is capable of breastfeeding but does not agree to forego breastfeeding from first dose of investigational medicinal product (IMP) through 30 days after the last dose of IMP.
-
The participant is an individual with potential for pregnancy but does not agree to use at least 1 form of highly effective contraception and 1 barrier method of contraception (preferably male condom) when engaging in heterosexual sex for the protocol specified duration after the last dose of IMP.
-
The participant is a sexually active, non-sterilized individual who produces sperm but does not agree to use a barrier method (preferably male condom) combined with at least 1 form of highly effective contraception for any partner(s) with potential for pregnancy when engaging in heterosexual sex for the protocol specified duration after the last dose of IMP.
-
In the investigator's opinion, the participant (and the participant's legally acceptable representative, if applicable per local regulations or determination) is unwilling and/or unable to understand and fully comply with clinical trial procedures and requirements (including digital tools and applications).
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Mezagitamab
Participants will receive mezagitamab injections, subcutaneously (SC), for approximately 22 weeks. |
Mezagitamab injections administered SC.
Otros nombres:
|
|
Comparador de placebos: Placebo
Participants will receive mezagitamab-matching placebo injections, SC for approximately 22 weeks. |
Mezagitamab-matching placebo injections administered SC. |
|
Experimental: Open-label Mezagitamab
Participants will receive mezagitamab injections, SC for approximately 22 weeks. |
Mezagitamab injections administered SC.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from Baseline in Proteinuria at Week 36
Periodo de tiempo: From Baseline to Week 36
|
Proteinuria will be assessed by urine protein to creatinine ratio (UPCR) calculated from a 24-hour urine collection. |
From Baseline to Week 36
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cambio desde el inicio en la tasa de filtración glomerular estimada (EGFR) en las semanas 52 y 104, respectivamente
Periodo de tiempo: Desde el inicio hasta las semanas 52 y 104
|
Desde el inicio hasta las semanas 52 y 104
|
|
|
Time From Baseline to the First Occurrence of Sustained Decline in eGFR of ≥30 Percent (%) From Baseline Over at Least 4 Weeks
Periodo de tiempo: From Baseline to Week 104
|
From Baseline to Week 104
|
|
|
Percentage of Participants Who Achieve ≥30% Reduction From Baseline in Proteinuria at Week 104
Periodo de tiempo: From Baseline to Week 104
|
From Baseline to Week 104
|
|
|
The Rate of Change in eGFR From Baseline at Week 104
Periodo de tiempo: From Baseline to Week 104
|
The rate of change in eGFR from baseline is measured as eGFR total slope. |
From Baseline to Week 104
|
|
Time from Baseline to the First Occurrence of Any of the Pre-specified Kidney Failure Composite Assessment Criteria
Periodo de tiempo: From Baseline to Week 104
|
The pre-specified assessment criteria will include: sustained decline in eGFR of ≥30% from baseline over at least 4 weeks; sustained eGFR <15 mL/min/1.73 m^2 over at least 4 weeks; initiation of maintenance dialysis defined as dialysis performed for at least 4 weeks; receipt of kidney transplant; or death from kidney failure. Time from baseline to first occurrence of any of the above assessment criteria would be reported. |
From Baseline to Week 104
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Study Director, Takeda
Publicaciones y enlaces útiles
Publicaciones Generales
Enlaces Útiles
- <p>Click here to ask Takeda's chatbot for comprehensive and easy-to-understand information about clinical trials - even across products and indications - in your local language.</p>
- <p>Click here for more information about this trial in easy-to-understand language, including a Plain Language Summary of the results if the trial has been completed.</p>
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- TAK-079-3001
- 2025-520825-19-00 (Ctis)
- 2025 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Criterios de acceso compartido de IPD
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .